Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection

Author(s): Michele Costanzo, Maria Anna Rachele De Giglio and Giovanni Nicola Roviello*

Volume 29 , Issue 1 , 2022

Published on: 29 July, 2021

Page: [4 - 18] Pages: 15

DOI: 10.2174/0929867328666210521164809


The aim of this review article is to summarize the knowledge available to date on prophylaxis achievements in the frame of the fight against Coronaviruses. This work will give an overview of what is reported in the recent literature on vaccines (under investigation or already developed like BNT162b2, mRNA-1273, and ChAdOx1-S) effective against the most pathogenic Coronaviruses (SARS-CoV-1, MERS-CoV-1, and SARS-CoV-2), with of course particular attention paid to those under development or already in use to combat the current COVID-19 (CoronaVIrus Disease 19) pandemic. Our main objective is to make a contribution to the comprehension, even at a molecular level, of what is currently ready for anti-SARS-CoV-2 prophylactic intervention, as well as to provide the reader with an overall picture of the most innovative approaches for the development of vaccines that could be of general utility in the fight against the most pathogenic Coronaviruses.

Keywords: Coronavirus, coronavirus infections, pandemics, COVID-19, HCoV, SARS-CoV, SARS-CoV-2, MERS- CoV, vaccine, BioNTech/Pfizer, Moderna, Oxford/AstraZeneca, BNT162b2, mRNA-1273, ChAdOx1-S, Vaxzevria.

© 2022 Bentham Science Publishers | Privacy Policy